You are now leaving myCME and connecting to our educational partner. myCME does not control content, practices, or other policies of the site you are entering.
1.50 / AMA PRA Category 1 Credit(s)TM
In acute coronary syndrome (ACS) patients, including those at high risk, antithrombotic therapy is key in the prevention of primary and recurrent atherothrombotic events, and also in the prevention of ischemic complications. In fact, the development of antiplatelet and antithrombotic medications and invasive vascular procedures have decreased the rates of mortality and subsequent cardiac events in ACS patients; yet patients experience recurrent clinical thrombotic events at a rate approaching 10% in the following year.
Utilizing an audience interactive format, this case-based activity will provide an opportunity for expert faculty dialogue/commentary, and will address the clinical implications of current guidelines for use of anticoagulant therapy in ACS patients, the role of thrombin in normal hemostasis and pathologic thrombosis, the relationship between bleeding and outcomes in ACS, and efficacy and safety data from recent and ongoing trials of novel anticoagulant therapies being studied in ACS patients.
Interventional cardiologists and other interested clinicians involved in the care and management of patients with ACS.
At the end of this online enduring material, participants should be able to:
AMA PRA Category 1 Credit(s)TM
For full program information, please click on “START ACTIVITY” button and follow the next click-through to reach this program site. Once you get to the “CME Access” site description page, you will review program information, program content, take the test and receive credit.
If you have any questions relating to the accreditation or your certificate for this activity, please contact the program sponsors.